Print pageHome » Siemens Embedded Multivariate Analysis Engine Features Umetrics Technology for PAT Solutions
Siemens Embedded Multivariate Analysis Engine Features Umetrics Technology for PAT Solutions
PharmaManufacturing.com
02/09/2010
Umetrics, a world leader in multivariate data analysis (MVDA) software, announces SIEMENS SIPAT, featuring embedded Umetrics MVDA for the implementation of Process Analytical Technology (PAT). SIPAT improves process understanding and, by permitting a focus on either specific units or total batch quality, its advanced process control allows continuous process improvement in both manufacturing and development applications, enabling real-time product release.
Umetrics’ SIMCA product family is tightly integrated and connected into the SIPAT environment, from model building and management of MVDA models through to the real-time application of these models. The use of MVDA models is enabled by the incorporation of SIMCA-Q, a calculation engine for real-time multivariate predictions of continuous and batch process results. Also, SIMCA-Batch On-Line (SBOL), a server – client MVDA solution, is interfaced with the SIPAT system.
These real-time quality assurance and fault detection solutions provide substantial cost-savings and improved product quality and process economics.
SIMCA-Q is the calculation engine of the SIMCA-suite of off-line and on-line software. This suite is used in research, development, and manufacturing for a variety of objectives and purposes all with one common goal; value from data. This platform makes the analysis efficient and easily interpretable, further enhanced by Umetrics’ expertise, training and constructive support.
For more information about SIPAT, please email info.sipat@siemens.com or visit www.siemens.com/sipat.
More News:
-
02/09/2012
Watchdog Fines Ernst & Young $2 million Over Medicis Pharma Corp. AuditsFrom Reuters.com
The watchdog board for corporate auditors on Wednesday said it has imposed a $2 million penalty, its largest fine ever, on accounting and consulting firm Ernst & Young LLP in a settlement involving past audits of Medicis Pharmaceutical Corp.
-
02/09/2012
FDA Issues Draft Guidance on Biosimilar Product Development
The U.S. Food and Drug Administration today issued three draft guidance documents on biosimilar product development to assist industry in developing such products in the United States.
-
02/08/2012
Biomedical Industry Loses Momentum in California, According to 2012 Report
Innovation slows as productivity in the Biomedical industry declines
-
02/02/2012
Pfizer Baby Boom? Pfizer's Official StatementFrom Pharmalot.com
About nine months from now, a new phenomenon may appear at a hospital near you: the Pfizer baby. Why? The drugmaker has taken the embarrassing step of recalling 1 million packets of birth control pills due to a packaging error. Hear EVP and CMO, Freda Lewis-Hall's read Pfizer's official statement.
-
02/02/2012
News: AstraZeneca To Cut 7,300 JobsFrom MarketWatch.com
Drug firm AstraZeneca on Thursday said it would cut approximately 7,300 jobs as part of an ongoing initiative to reduce costs and drive innovation.
-
02/01/2012
Pfizer Recalls 1 Million Birth Control Packs for Error That Could Cause Unintended PregnancyFrom WashingtonPost.com
Pfizer Inc. is recalling 1 million packets of birth control pills due to a packaging error that could raise the risk of an accidental pregnancy by leaving women with an inadequate dose. The problem affects 14 lots of Lo/Ovral-28 tablets and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets. Both products are manufactured by Pfizer and marketed in the U.S. by Akrimax Rx Products under the Akrimax Pharmaceuticals brand.
-
01/26/2012
News: Abbott Labs Cuts 700 Manufacturing JobsFrom WashingtonPost.com
Medical device and drugmaker Abbott Laboratories said Wednesday it will lay off 700 employees as part of ongoing restructuring efforts. A company spokeswoman said most of the layoffs will affect employees who manufacture the company’s heart stents and diagnostic tests.
- 01/24/2012 ISPE Announces 2012 FOYA Winners
- 01/24/2012 Genzyme Gains Approval for Framingham Site, a Boost to Fabrazyme Production
-
01/19/2012
Big Pharma Execs May Wish They'd Never Heard Of Paula DeenFrom Forbes.com
Novo Nordisk has nabbed Paula Deen as a new spokeswoman to help raise awareness about type 2 diabetes. Many in the drug industry wish it weren’t so, but without major legal and regulatory changes, such matches between celebs and drug firms are as certain as the sun rising in the east.
- All news »
Get Connected Now!
- Featured White Papers
Sponsored Links
